Complications from cancer surgical care incur extremely high costs

Although complications from surgical care for cancer patients may seem infrequent, the costs associated with such outcomes are extremely high, according to researchers.

“It is widely known that outcomes after cancer surgery vary widely, depending on interactions between patient, tumor, neoadjuvant therapy, and provider factors,” said Marah Short, a senior research analyst for Rice University's Baker Institute's Health Policy Forum in Houston, Texas. “An area of cancer care that has received little attention is the influence of complications on medical outcomes and costs of care. In our study, we found consistently higher costs associated with cancer surgery complications. Improved patient outcomes and substantial health care savings could be achieved by targeting these complicating factors for quality improvement.”

The study's findings come against the backdrop of rising cancer care costs in the United States, which were estimated at $124.6 billion in 2010 and could rise by 66% to $207 billion by 2020.

In cancer treatment, unlike many benign conditions, there tends to be a higher threshold of tolerance for complications, the authors said. In addition, the direct cause of complications is more difficult to determine as there are complex interactions between patient, tumor, multimodality therapy, and provider factors that contribute to adverse outcomes.

In the study, published in Cancer (2013; doi:10.1002/cncr.28527), the authors used the Agency for Healthcare Research and Quality's Patient Safety Indicators (PSIs) to identify patient safety-related complications in Medicare claims data. PSIs are a set of transparent outcome measures that provide information on potential in-hospital complications and adverse events after surgeries, procedures, and childbirth. They analyzed hospital and inpatient physician claims from all 50 US states for the years 2005 through 2009 for six cancer resections: colectomy, rectal resection, pulmonary lobectomy, pneumonectomy, esophagectomy, and pancreatic resection.

They found overall PSI rates for complications arising from the six procedures ranged from a low of 0.01% for postoperative hip fracture to a high of 2.58% for respiratory failure. Rates of postoperative respiratory failure, death among inpatients with serious treatable complications, postoperative thromboembolism, and accidental puncture/laceration were more than 1% for all six cancer operations.

Several PSIs—including decubitus ulcer, postoperative thromboembolism, and death among surgical inpatients with serious treatable complications—raised hospitalization costs by more than 20% for most types of cancer surgery. Postoperative respiratory failure resulted in a cost increase of more than 50% for all cancer resections.

“These data indicate that, even in the complex cancer care environment, in which many controllable and uncontrollable variables may contribute to complications, improvements in patient safety indicators are highly likely to reduce costs,” Short said. “We may not have identified all of the complication measures that are important determinants of surgeon and hospital costs. However, because we know so little about the links between provider volume, care processes, complications and costs, this analysis represents an important first step in examining these relations.”

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs